Nurix Therapeutics, Inc.

(c) Director and Section 16 Officer Rule 10b5-1 Trading Arrangements

On February 3, 2026, Hans van Houte, Chief Financial Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (van Houte Plan), providing for the potential sale of up to 173,860 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Mr. van Houte and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Mr. van Houte. The shares will be sold at the times and prices specified in the van Houte Plan. The van Houte Plan expires on April 30, 2027, or upon the earlier completion of all authorized transactions thereunder.

On February 27, 2026, Gwenn M. Hansen, Chief Scientific Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (Hansen Plan), providing for the potential sale of up to 52,460 shares of the Company’s common stock, including shares issuable upon the exercise of option awards previously granted to Dr. Hansen and shares to be acquired upon the vesting and settlement of restricted stock units previously granted to Dr. Hansen. The shares will be sold at the times and prices specified in the Hansen Plan. The Hansen Plan expires on May 31, 2027, or upon the earlier completion of all authorized transactions thereunder.

No other director or Section 16 officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the three months ended February 28, 2026.